Clear Street raised the firm’s price target on Editas Medicine (EDIT) to $4.60 from $4 and keeps a Buy rating on the shares following the Q3 report. The company maintained previously stated timelines for EDIT-401, the analyst tells investors in a research note. The firm sees $1.8B in peak sales and a 10% likelihood of success.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine reports Q3 EPS (28c), consensus (38c)
- Editas Medicine Inc. (EDIT) Q3 Earnings Cheat Sheet
- FDA to speed up gene editing therapy approvals, Bloomberg reports
- Video: This stock is dragging down the in vivo gene editing therapy space
- Editas Medicine’s Long-Term Study on EDIT-301: A Potential Game-Changer for Hemoglobinopathies